PURPOSE: Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea and flushing, can be debilitating and occasionally life-threatening. Although symptom relief is available with octreotide, the disease eventually becomes refractory to octreotide, leaving no proven treatment options. The goal of this study was to evaluate the clinical effect of using (90)Y-edotreotide to treat symptomatic patients with carcinoid tumors. PATIENTS AND METHODS: Patients enrolled had metastatic carcinoid, at least one sign/symptom refractory to octreotide, and at least one measurable lesion. Study treatment consisted of three cycles of 4.4 GBq (120 mCi) (90)Y-edotreotide each, once every 6 weeks. RESULTS: Ninety patients were enrolled in the study. Using Southwest Oncology Group tumor response criteria, 67 (74.%) of 90 patients (95% CI, 65.4% to 83.4%) were objectively stable or responded. A statistically significant linear trend toward improvement was demonstrated across all 12 symptoms assessed. Median progression-free survival was significantly greater (P = .03) for the 38 patients who had durable diarrhea improvement than the 18 patients who did not (18.2 v 7.9 months, respectively). Adverse events (AEs) were reported in 96.7% (87 of 90) of patients. These AEs consisted primarily of reversible GI events (76 of 90), which could be caused in part by concomitant administration of amino acid solution given to reduce radiation exposure to the kidneys. There was one case each of grade 3 oliguria and grade 4 renal failure, each lasting 6 days. CONCLUSION: (90)Y-edotreotide treatment improved symptoms associated with malignant carcinoid among subjects with no treatment alternatives. Treatment was well-tolerated and had an acceptable expected AE profile.
PURPOSE: Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea and flushing, can be debilitating and occasionally life-threatening. Although symptom relief is available with octreotide, the disease eventually becomes refractory to octreotide, leaving no proven treatment options. The goal of this study was to evaluate the clinical effect of using (90)Y-edotreotide to treat symptomatic patients with carcinoid tumors. PATIENTS AND METHODS: Patients enrolled had metastatic carcinoid, at least one sign/symptom refractory to octreotide, and at least one measurable lesion. Study treatment consisted of three cycles of 4.4 GBq (120 mCi) (90)Y-edotreotide each, once every 6 weeks. RESULTS: Ninety patients were enrolled in the study. Using Southwest Oncology Group tumor response criteria, 67 (74.%) of 90 patients (95% CI, 65.4% to 83.4%) were objectively stable or responded. A statistically significant linear trend toward improvement was demonstrated across all 12 symptoms assessed. Median progression-free survival was significantly greater (P = .03) for the 38 patients who had durable diarrhea improvement than the 18 patients who did not (18.2 v 7.9 months, respectively). Adverse events (AEs) were reported in 96.7% (87 of 90) of patients. These AEs consisted primarily of reversible GI events (76 of 90), which could be caused in part by concomitant administration of amino acid solution given to reduce radiation exposure to the kidneys. There was one case each of grade 3 oliguria and grade 4 renal failure, each lasting 6 days. CONCLUSION: (90)Y-edotreotide treatment improved symptoms associated with malignant carcinoid among subjects with no treatment alternatives. Treatment was well-tolerated and had an acceptable expected AE profile.
Authors: M de Jong; W A Breeman; B F Bernard; W H Bakker; T J Visser; P P Kooij; A van Gameren; E P Krenning Journal: J Nucl Med Date: 2001-12 Impact factor: 10.057
Authors: Christian Waldherr; Miklos Pless; Helmut R Maecke; Tilmann Schumacher; Armin Crazzolara; Egbert U Nitzsche; Andreas Haldemann; Jan Mueller-Brand Journal: J Nucl Med Date: 2002-05 Impact factor: 10.057
Authors: François Jamar; Raffaella Barone; Isabelle Mathieu; Stéphan Walrand; Daniel Labar; Pascal Carlier; Joëlle de Camps; Horst Schran; TianLing Chen; M Charles Smith; Hakim Bouterfa; Roelf Valkema; Eric P Krenning; Larry K Kvols; Stanislas Pauwels Journal: Eur J Nucl Med Mol Imaging Date: 2003-02-12 Impact factor: 9.236
Authors: Rudolf Arnold; Anja Rinke; Klaus-Jochen Klose; Hans-Helge Müller; Matthias Wied; Karin Zamzow; Christina Schmidt; Carmen Schade-Brittinger; Peter Barth; Roland Moll; Michael Koller; Michael Unterhalt; Wolfgang Hiddemann; Martin Schmidt-Lauber; Marianne Pavel; Christian N Arnold Journal: Clin Gastroenterol Hepatol Date: 2005-08 Impact factor: 11.382
Authors: M di Bartolomeo; E Bajetta; R Buzzoni; L Mariani; C Carnaghi; L Somma; N Zilembo; A di Leo Journal: Cancer Date: 1996-01-15 Impact factor: 6.860
Authors: David Bushnell; Yusuf Menda; Thomas O'Dorisio; Mark Madsen; Sara Miller; Thomas Carlisle; Shayne Squires; Daniel Kahn; Wayne Walkner; Mary Connolly; Sue O'Dorisio; Mark Karwal; James Ponto; Hakim Bouterfa Journal: Cancer Biother Radiopharm Date: 2004-02 Impact factor: 3.099
Authors: Eduardo A Perez; Leonidas G Koniaris; Sarah E Snell; Juan C Gutierrez; William E Sumner; David J Lee; Nicole C Hodgson; Alan S Livingstone; Dido Franceschi Journal: World J Surg Date: 2007-05 Impact factor: 3.352
Authors: Roeland F de Wilde; Barish H Edil; Ralph H Hruban; Anirban Maitra Journal: Nat Rev Gastroenterol Hepatol Date: 2012-02-07 Impact factor: 46.802
Authors: L Bodei; J Mueller-Brand; R P Baum; M E Pavel; D Hörsch; M S O'Dorisio; T M O'Dorisio; T M O'Dorisiol; J R Howe; M Cremonesi; D J Kwekkeboom; John J Zaknun Journal: Eur J Nucl Med Mol Imaging Date: 2013-05 Impact factor: 9.236
Authors: Nancy Sharma; Boris G Naraev; Eric G Engelman; M Bridget Zimmerman; David L Bushnell; Thomas M OʼDorisio; M Sue OʼDorisio; Yusuf Menda; Jan Müller-Brand; James R Howe; Thorvardur R Halfdanarson Journal: Pancreas Date: 2017-02 Impact factor: 3.327